logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5660.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5660.produseast1
Showing 1 - 6 of 6 Items
Showing 1 - 6 of 6 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients

Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bayona J,  et al.
2012-08-28 • PLOS Medicine
2012-08-28 • PLOS Medicine
Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic, expensive, and has generally poor outcomes. We undertook an individual patient data meta-analysis to assess the ...
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research

Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis

Ettehad D, Schaaf HS, Seddon JA, Cooke GS, Ford NP
2012-02-27 • Lancet Infectious Diseases
2012-02-27 • Lancet Infectious Diseases

Multi- and extensively drug-resistant tuberculosis in Latvia: trends, characteristics and treatment outcomes

Kuksa L, Riekstina V, Leimane V, Ozere I, Skenders G,  et al.
2014-10-21 • Public Health Action
2014-10-21 • Public Health Action
SETTING
Drug-resistant tuberculosis (TB) is an important public health problem in Latvia.

OBJECTIVE
To document trends, characteristics and treatment outcomes of registe...

Treatment outcomes among drug-susceptible tuberculosis patients in Latvia, 2006–2010

Lucenko I, Riekstina V, Perevoscikovs J, Mozgis D, Khogali MA,  et al.
2014-10-21 • Public Health Action
2014-10-21 • Public Health Action
SETTING
Latvia, an Eastern European country with a high burden of tuberculosis (TB).

OBJECTIVE
To describe treatment outcomes among new drug-susceptible TB patients and ...

Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis [Review article]

Toczek A, Cox HS, du Cros PAK, Cooke GS, Ford NP
2012-12-04 • International Journal of Tuberculosis and Lung Disease
2012-12-04 • International Journal of Tuberculosis and Lung Disease
BACKGROUND: Scaling up treatment for multidrug-resistant tuberculosis is a global health priority. However, current treatment regimens are long and associated with side effects, and defa...

Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis

Cox V, Brigden G, Crespo RH, Lessem E, Lynch S,  et al.
2018-04-01 • International Journal of Tuberculosis and Lung Disease
2018-04-01 • International Journal of Tuberculosis and Lung Disease
SETTING
The World Health Organization recommended two new drugs, bedaquiline (BDQ) and delamanid (DLM), for the treatment of multidrug-resistant tuberculosis (MDR-TB) in 2013 and 201...